CORC

在结果中检索

CORC

浏览/检索结果: 共19条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer 期刊论文
2019, 卷号: 118, 页码: 169-177
作者:  Huober, Jens;  Holmes, Eileen;  Baselga, Jose;  de Azambuja, Evandro;  Untch, Michael
收藏  |  浏览/下载：10/0  |  提交时间：2020/01/03
Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial 期刊论文
2017, 卷号: 35
作者:  Huober, Jens Bodo;  Holmes, Eileen McCormick;  Baselga, Jose;  De Azambuja, Evandro;  Untch, Michael
收藏  |  浏览/下载：2/0  |  提交时间：2020/01/04
Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T -> L) or their combination (L plus T) in the adjuvant tre 会议论文
JOURNAL OF CLINICAL ONCOLOGY, 2017-05-20
作者:  Moreno-Aspitia, Alvaro;  Holmes, Eileen McCormick;  Jackisch, Christian;  De Azambuja, Evandro;  Boyle, Frances M.
收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04
Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial 会议论文
JOURNAL OF CLINICAL ONCOLOGY, 2017-05-20
作者:  Huober, Jens Bodo;  Holmes, Eileen McCormick;  Baselga, Jose;  De Azambuja, Evandro;  Untch, Michael
收藏  |  浏览/下载：10/0  |  提交时间：2020/01/04
Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T -> L) or their combination (L plus T) in the adjuvant tre 期刊论文
2017, 卷号: 35
作者:  Moreno-Aspitia, Alvaro;  Holmes, Eileen McCormick;  Jackisch, Christian;  De Azambuja, Evandro;  Boyle, Frances M.
收藏  |  浏览/下载：4/0  |  提交时间：2020/01/04
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial 期刊论文
LANCET ONCOLOGY, 2016, 卷号: 17, 期号: 3
作者:  Harbeck, Nadia;  Huang, Chiun-Sheng;  Hurvitz, Sara;  Yeh, Dah-Cherng;  Shao, Zhimin
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/06
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial 期刊论文
2016, 卷号: 17, 期号: 3, 页码: 357-366
作者:  Harbeck, Nadia;  Huang, Chiun-Sheng;  Hurvitz, Sara;  Yeh, Dah-Cherng;  Shao, Zhimin
收藏  |  浏览/下载：1/0  |  提交时间：2020/01/04
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial 期刊论文
2016, 卷号: 34, 期号: 10, 页码: 1034-+
作者:  Piccart-Gebhart, Martine;  Holmes, Eileen;  Baselga, Jose;  de Azambuja, Evandro;  Dueck, Amylou C.
收藏  |  浏览/下载：10/0  |  提交时间：2020/01/04
Randomized Phase III trial of afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one prior trastuzumab treatment: LUX-Breast 1 会议论文
作者:  Harbeck, Nadia;  Huang, Chiun-Sheng;  Hurvitz, Sara;  Yeh, Dah-Cherng;  Shao, Zhimin
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/19
Randomized Phase III trial of afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one prior trastuzumab treatment: LUX-Breast 1 会议论文
CANCER RESEARCH, 2015-05-01
作者:  Harbeck, Nadia;  Huang, Chiun-Sheng;  Hurvitz, Sara;  Yeh, Dah-Cherng;  Shao, Zhimin
收藏  |  浏览/下载：2/0  |  提交时间：2020/01/04

©版权所有 ©2017 CSpace - Powered by CSpace